Introduction
Acyclonucleoside is a term broadly applied to certain heterocycles substituted with a hydroxylated acyclic moiety structurally related to the glycon of natural nucleosides. The diverse structures from this class of compounds that have been synthesized and evaluated for their antiviral efficacy have been the subject of several review articles (Remy & Secrist, 1985; Chu & Cutler, 1986; Herdewijn, 1992; Johansson, 1993) . From initial studies, the acyclonucleosides of guanine emerged as the drugs of choice for the treatment of certain virus-induced pathologies. Acyclovir [9-(2-hydroxyetll0xymethyl)guanine; ACV; Schaeffer et al., 1978] is currently marketed for the treatment of herpes simplex virus (HSV) infections, whereas ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl}guanine; D HPG; Martin et al., 1983] is often the standard against which other drugs are measured for their effect against human type 1 or murine cytomegalovirus. It was found to have a cytotoxicity profile similar to that of ganciclovir (DHPG). The antiviral effect was found to be sensitive to the initial viral input and the time of addition during the virus replication cycle. Significantly, the compound was found to have equal anti-HCMV activity, against standard virus strains, to DHPG, but also showed potent activity against DHPG-resistant virus strains, except for a strain mutated in the UL97 (phosphotransferase) gene. Keywords: thiazolo[4, pyrimidine; human cytomegalovirus; acyclonucleoside. cytomegalovirus (HCMV) infection. These two molecules retain the ether portion of the ribofuranose moiety of guanosine. Acyclonucleosides such as HBG [9-(4-hydroxybutyl)guanine; Larsson et al., 1983] in which the ether oxygen is replaced by carbon (carba-acyclonucleosides) have similarly shown potent anti-herpesvirus activity. The synthesis and anti-herpesvirus activity of acyclo-and carba-acycloguanine nucleosides that are unsaturated in the glycon moiety have also been reported (Larsson et al., 1986; Haines et al., 1987; Phadtare et al., 1991; Hua et al., 1987; Ashton et al., 1988; Lazrek et al., 1995) . Studies of both the Z (Larsson et ai., 1986) and E (Hua et at., 1987) isomers of 9-( 4-hydroxy-2-buten-1-yl)guanine, analogues of HBG, indicated that the former geometric isomer had the superior antiviral activity as an inhibitor ofHSV-1 and HSV-2. The observation that some of the active acyclonu-cleosides exert their antiviral effect at the triphosphate level by interfering with viral DNA polymerase (Keller et al., 1981; Elion, 1982 Elion, , 1983 Derse et al., 1981; Miller & Miller, 1980) stimulated interest in the synthesis and study of acyclonucleotide mimics which led to a second generation of anti-herpesvirus agents (De Clercq, 1994) . Similarly, a variety of biological activities have been ascribed to certain phosphonoalkenylguanines (Halazy et al., 1991; Harnden et al., 1993) .
Irrespective of the considerable effort to date, the search for agents to augment the armamentarium available for the treatment of HCMV infection continues, since this pathogen is responsible for a variety of serious disorders in individuals with an undeveloped or compromised immune system (Collaborative DHPG Treatment Study Group, 1986; Balfour, 1990; Chrisp & Clissold, 1991) . The effectiveness of the three drugs approved for the treatment of HCMV, ganciclovir, foscarnet and cidofovir, is limited by their toxicity (Jacobson, 1992; Meyers, 1991; Polis et al., 1995) as well as the development of resistant viral strains Jacobson et al., 1991) . VVe recently reported on the synthesis (Lewis et al., 1995) and potent in vitro anti-HCMV activity (Lewis et al., 1994) of certain 3alkyl derivatives of 5-aminothiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione (1), the (Z)-2-pentenyl derivative (2a; T01132) being the more effective member of the series studied. In addition to exploiting the antiviral activity of these alkylguanine congeners, we were interested in the biological evaluation of both saturated and unsaturated analogues of known antiviral acyclonucleosides and carbaacyclonucleosides containing this heterocycle. The synthesis and in vitro anti-HCMV activity of certain acyclonucleosides and acyclonucleotide mimics derived from 1 are the subject of this report.
Materials and Methods: Chemistry

General methods and sources
Melting points were determined with a Thomas-Hoover Unimelt melting point apparatus and are uncorrected. UV spectra (sh, shoulder) were recorded with a Hewlett-Packard 8452A diode array spectrophotometer. IR spectra were recorded in KEr with a Perkin-Elmer 1420 IR spectrophotometer. IH NMR spectra were recorded in DMSO-d 6 with a Brucker AJ\lI400 wide bore spectrometer and the chemical shifts are expressed in b (p.p.m.) relative to tetramethylsilane (TJVIS) as an internal standard (s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad) . Elemental analyses were performed by Qpantitative Technologies (Whitehouse, N.J., USA) and the presence of H 20 as indicated by elemental analysis was verified by 'n NJVIR spectroscopy.
Thin layer chromatography (TLC) was conducted on aluminum plates coated (0.2 mm) with silica gel 60F 254 (EJVI Science) and components were visualized by UV absorbance. EM Science silica gel 60 A (230-400 mesh) 54 was used for all column chromatographic separations. Preparative HPLC used a Waters Delta Prep 3000 equipped with a model 991 PDA detector and the purifications were accomplished on a PrepPAK 500 CIS column. Evaporations were carried out at a temperature ,,35°C and under diminished pressure for solvents with bp <80°C or under high vacuum for higher boiling solvents. DHPG was a gift from Syntex Corporation, ACV was a gift from GlaxoWellcome, (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) was a gift form Gilead Sciences and 2',3'-dideoxycytidine (ddC) was obtained from the National Institutes of Health (Bethesda, JVId., USA). All other chemicals used were reagent grade and were not further dried or purified unless otherwise noted.
5-
A mixture of 1 (Baker & Chatfield, 1970 ) (0.46 g, 2.5 mmol), anhydrous DMF (25 ml) and NaH (80% dispersion in mineral oil, 0.076 g, 2.53 mmol) was stirred at ambient temperature for 1 h. 4-Bromobutyl acetate (0.4 ml, 2.76 mmol) was added and the mixture was heated at 80°C (oil bath) for 4 h. The mixture was evaporated and the residue was stirred with H 20 (25 ml). The solid produced was collected by filtration, crystallized from a J\lIeOH-H 20 mixture and then dried in vacuum over P 20S for 2 days; 0.38 g (1.27 mmol, 51%), m.p. 189-190°C; IR V m a ' 3420, 3320 and 3220 (NH, NH 2 ) , 1730 (C=O) and 1705 (C=O) cm"; UV lema, [nm (E, mM)] (pH 1) 302 (9.35), 250 (8.18), 222 (29.9); (MeOH) 302 (9.31), 248 (8.71), 222 (29.3); (pH 11) 292 (7.93), 250 (7.67), 224 (11.3); 'n NMR b 1.54-1.58 (m,2 H, CH z ), 1.65-1.70 (rn, 2 H, CH 2 ) , 1.98 (s, 3 H, CH 3 ) , 3.78 (t,2 H, NCH 2 ) , 4.01 (t,2 H, OCH 2 ) , 6.81 (br s, 2 H, NH 2 ) and 10.97 (br s, 1 H, NH). Anal. calcd for CnHI4N404S (298.32): C, 44.29; H, 4.73; N, 18.78. Found: C, 44.09; H, 4.76; N, 18.57 .
5-Am ino-3-(4-hyd roxybutyl)th iazolo [4,5d]pyrimidine-2,7(3H,6H)-dione (2c) A mixture of 2b (0.23 g, 0.771 mmol) and concentrated NH 40H (10 ml) was placed in a pressure bottle and stirred at ambient temperature for 18 h. The solution was evaporated in vacuum and the residual solid was stirred with H 20 (10 ml). The solid was collected by filtration, crystallized from a JVIeOH-H 20 mixture and dried in vacuum at 80°C for 3 days; 0.12 g (0.468 mmol, 61%), m.p. 258-260°C; IR v m ax 3305 (OH, NH, NH 2), 3180 (NH, NH 2) and 1650 broad (C=O, C=N) cm-\ UV lema, [nm (E, mM)] (pH 1) 302 (9.83), 250 (8.47), 222 (30.3); (H 20) 302 (9.70),250 (8.37),222 (30.4); (pH 11) 292 (7.71),250 (7.47),224 (9.62); IH NMR b 1.35-1.42 (rn, 2 H, CH z ), 1.60-1.68 (rn, 2 H, CH 2 ) , 3.36-3.41 (rn, 2 H, OCH 2 ) , 3.76 (t, 2 H, NCH 2 ), 4.40 (t, 1 H, OR), 6.89 (br s, 2 H, NH 2 ) and 11.06 (br s, 1 H, NH). Anal. calcd for C 9H 12N403S (256.28): C, 42.18; H, 4.72: N, 21.86. Found: C, 42.05; H, 4.67: N, 21.73 .
5-Amino
A mixture of I (0.53 g, 2.88 mmol), anhydrous DMF (20 ml) and NaH (80% dispersion in mineral oil, 0.087 g, 2.9 mmol) was stirred at ambient temperature for 2 h and then cooled in an ice bath (5°C). (2-Acetoxyethoxy)methyl bromide (Robins & Hatfield, 1982 ) (0.35 ml, 3.02 mmol) was added over a 5 min period and the mixture was stirred in the cold for 30 min more. The solution was evaporated in vacuum and then 25 ml of H 20 was added. The pH of the mixture was adjusted to 6 by the addition of AcOH and then the mixture was stored in the cold (5°C) for 16 h. The solid produced was collected by filtration and then extracted with hot lVIeOH (50 ml). Silica gel (10 g) was added to the lVIeOH solution and the mixture was then evaporated. The dry powder was placed on top of a silica gel column (5.5x12 ern) and the column was flash-eluted with progressively increasing concentrations ofMeOH in CH 2Cl2: 0% MeOH in 0.51 CH 2Cl2; 1% in 0.5 1; 2% in 0.5 1; and 5% in 2 1. Eluate containing the product was evaporated and the residue was crystallized from an EtOH-H 20 mixture, then dried in vacuum at 80°C for 2 days; 0.08 g (0.266 mmol, 28%), m.p. 173-176°C; IR "max 3520, 3450, 3350 and 3150 (NH, NH 2), 1720 (C=O, ester), 1675 (C=O) and 1640 (C=C, C=N) cm"; UV A max [rim (E, mlVI)] (pH 1) 300 (8.95),248 (8.39),216 (25.8); (MeOH) 302 (8.49),246 (8.10), 216 (24.0); (pH 11) 290 (6.88), 246 (7.52); IH , 4.03; N, 18.66. Found: C, 39.79; H, 4.07; N, 18.36 .
A mixture of compound 2d (0.3 g, 0.999 mrnol) and concentrated NH 40H (10 ml) was placed in a pressure bottle and stirred at ambient temperature for 3 h. The solution was evaporated in vacuum and the residual solid was stirred with H 20 (10 ml}, The mixture was neutralized (AcOH) and the solid was collected by filtration, then dried in vacuum over P 205 for 20 h; 0.145 g (0.56 mmol, 56%). The solid was crystallized from H 20 and then dried in vacuum at 70°C for 2 days; m.p. 230-232°C; IR "max 3305 (OH, NH, NH 2), 3180 (NH, NH 2) and 1650 broad (C=O, C=N, C=C) cm"; UV A..nax [nm (E, mM)] (pH 1) 300 (9.93),248 (9.26), 216 (28.5); (H 20) 300 (9.74),248 (9.08),216 (28.1); (pH 11) 290 (7.70),246 (8.38),226 (7.37); IH NMR () 3.45 (t, 2 H, CH 2 ) , 3.54 (t, 2 H, CH 2 ) , 4.63 (t, 1 H, 011),5.14 (s, 2 H, OCH 2N), 6.95 (br s, 2 H, NH 2 ) and 11.2 (br s, 1 H, N11). Anal. calcd for C SHlON 404S Antiviral Chemistry & Chemotherapy 9:1 Thiazolo[4,5-d]pyrimidines: anti-HCMV activity (258.26): C, 37.21; H, 3.90; N, 21.69. Found: C, 37.15; H, 3.88; N, 21.29 .
5-Am ino
A mixture ofl (0.5 g, 2.71 mmol), anhydrous DlVIF (20 ml) and NaH (80% dispersion in mineral oil, 0.084 g, 2.8 mmol) was stirred and cooled in an ice bath (5°C) for 1 h. 2-(Bromomethoxy)-1,3-propanediyl dibenzoate (Beauchamp et al., 1988) (0.88 g, 3.0 mmol) was added. The mixture was stirred with continuous cooling for 0.5 h and then without cooling for 4 h. The mixture was evaporated in vacuum and then H 20 (50 ml) was added. The solid produced was collected by filtration and extracted with MeOH (100 ml). Silica gel (25 g) was added to the extract and the mixture was evaporated. The dry powder was placed on top of a silica gel column (5.5x18 ern) and the column was flasheluted with progressively increasing concentrations of MeOH in CH 2C12: 1% MeOH in 11 CH 2Cl2; 2% in 11; 3% in 1 1; 5% in 1 1. The eluate containing the homogeneous product was evaporated and the solid residue was dried in vacuum at 65°C for 1 day; 0.32 g (0.639 mmol, 23%), m.p. >85°C (wide range); IR "max 3440, 3340 and 3205 (NH, NH 2 ) , 1720 (C=O) and 1660 (C=O, C=N) cm"; UV Am' LX [nrn (E, mlVI)] (pH 1) 302 (7.68), 234 (27.7), 218 (31.4); (MeOH) 302 (7.46), 230 (27.2), 218 (32.1); (pH 11) 286 (6.85), 234 (27.4) . IH NlVIR () 4.34-4.39 (rn, 2 H, CH 2 ) , 4.48-4.58 (rn, 3 H, CH 2 and C11), 5.34 (s, 2 H, NCH 2 ) , 6.89 (br s, 2 H, NH 2 ) , 7.48-7.52 (rn, 4 H, 4 Ar11), 7.64-7.68 (m,2 H, 2 Ar11), 7.89 (s, 2 H, 2 Ar11), 7.91 (s, 2 H, 2 Ar11) and 11.05 (br s, 1 H, N11). Anal. calcd for CnH2oN407So0.25H20 (501.01): C, 55.14; H, 4.12; N, 11.18. Found: C, 54.96; H, 4.26; N, 10.90 .
A mixture of 2f (0.4 g, 0.798 mmol), sodium methoxide (0.2 g) and lVIeOH (100 ml) was stirred at ambient temperature for 18 h. Amberlite IR-120(H+) (1 g, washed with H 20 then MeOH) was added and the mixture was stirred until neutral. The resin was removed by filtration and the lVleOH solution was evaporated. The residue was triturated with Et 20 (2x50 ml) and then crystallized from H 20. The crystalline product was dried in vacuum at 90°C for 2 days; 0.115 g (0.399 mmol, 50%), m.p. 256-258°C; IR Y max 3370, 3210 and 3170 (NH, NH 2, OH), and 1650 broad (C=O, C=N) cm-\ UV A nm [nrn (E, mM)] (pH 1) 302 (9.62), 248 (9.16), 216 (27.6); (MeOH) 302 (9.08),248 (8.43),216 (25.0); (pH 11) 292 (7.37),246 (8.04); IH NlVIR () 3.28-3.34 (rn, 2 H, CH 2 ) , 3.41-3.46 (rn, 2 H, CH 2 ) , 3.66 (t, 1 H, C11), 4.53 (t, 2 H, 2 011),5.24 (s, 2 H, NCH 2 ) , 6.91 (br s, 2 H, NH 2 ) and 11.13 (br s, 1 H, N11). Anal. calcd for C 9H12N40SS (288.28): C, 37.50; H, 4.20; N, 19.43. Found: C, 37.43; H, 4.08; N, 19.23.
The compound was prepared, as described for 2b, from 1 (3 g, 16.29 mmol) and 4-chloromethyl-2,2-dimethyl-l,3dioxolane (2.4 ml, 17.5 mmol) with a reaction temperature of 140°C for 42 h. After cooling, the mixture was evaporated in vacuum and then H 20 (100 ml) was added. The mixture was stirred, then filtered and the aqueous filtrate was taken to dryness by repeated coevaporation with EtOH. The residue was purified by flash column (5.5x21 em) chromatography, eluting with progressively increasing concentrations of MeOH in CH 2C12: 0% MeOH in 0.5 1 CH 2C12; 1% in 11; 2% in 11; 5% in 3.5 1; 10% in 11; and then dried in vacuum for 2 days; 1.79 g (6.0 mmol, 37%).
A spectroscopically and chromatographically identical sample of 2h obtained from a pilot reaction was dried in vacuum over P20S (R,S)-5-Amino-3-(2,3-dihydroxy-propyl)thiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione (2i) A mixture of 2h (0.2 g, 0.67 mmol) and a solution of hydrogen chloride in MeOH (10%, 20 ml) was protected from moisture and stirred at ambient temperature for 45 min. The solution was evaporated and the residue was stirred with H 20 (20 ml). The mixture was immediately made basic (pH 9) by the addition of concentrated NH 40H and then acidified (pH 6) with AcOH. The mixture was allowed to stand for 2 h and then the solid was collected by filtration, washed with H 20 (50 ml) and dried in vacuum at 95°C for 16 h; 0.1 g (0.387 mmol, 57%), m.p. 248-254°C; IR v max 3360 broad (OH, NH, NH 2 ) and 1620 broad (C=O, C=N) ern"; UV 
5-Amino
The compound was prepared, as described for 2b, from 1 (1.2 g, 6.52 mmol) and (Z)-1,4-dichloro-2-butene (0.75 ml, 7.13 mmol) at a reaction temperature of 120°C for 8 h. The product was purified by flash column (5.5x20 ern) chromatography, eluting with progressively increasing 56 concentrations of MeOH in CH 2C12: 1% MeOH in 1 1 CH 2C12; 2% in 1 1; 3% in 1 1; 5% in 2 1. The eluate containing the homogeneous product was evaporated and the solid residue was dried in vacuum over P205 for 16 h; 0.7 g (2.57 mmol, 39%), m.p. 200-202°C (eff.); IRv max 3430,3310 and 3180 (NH, NH 2) and 1660 broad (C=O, C=N, C=C) ern"; UV A max [nm (E, mM)] (pH 1) 302 (9.21), 250 (8.03), 220 (28.7); (MeOH) 302 (8.92), 250 (8.24), 220 (28.1); (pH 11) 292 (7.63), 250 (7.57), 224 (9.43); IH NMR 0 4.39 (d,2 H, CH 2 ) , 4.46 (d,2 H, CH 2 ) , 5.63-5.68 (m, JID'-H3' 10.8 Hz, 1 H, CIl), 5.77-5.84 (rn, JID'-H3' 10.8 Hz, 1 H, CIl), 6.85 (br s, 2 H, NH 2 ) and 11.05 (br s, 1 H, NIl). Anal. calcd for C 9H9C1N402S (272.71): C, 39.64; H, 3.33; Cl, 13.00; N, 20.54. Found: C, 39.60; H, 3.29; Cl, 12.69; N, 20.17 .
The compound was prepared and purified as described for 2j, from 1 (1.2 g, 6.52 mmol) and (E)-1,4-dichloro-2butene (0.75 ml, 7.1 mmol) at a reaction temperature of (21) A mixture of 2j (0.81 g, 2.97 mmol) and 0.1 M hydrochloric acid (80 ml) was heated at reflux for 1.5 h. Upon cooling a solid separated which was collected by filtration and dried in vacuum at 100°C for 16 h. The solid was extracted with hot MeOH (100 ml). Silica gel (25 g) was added to the MeOH solution and the mixture was evaporated. The dry powder was placed on top of a silica gel column (5.5x13 em) and the column was flash eluted with progressively increasing concentrations ofMeOH in CH 2C12: 0% MeOH in 11; 2% in 11; 5% in 11; 10% in 1 1; 20% in 2 1. The eluate containing the homogeneous product was evaporated and the residual solid was dried in vacuum at 100°C for 16 h; 0.18 g (0.708 mmol, 24%); m.p. 250-254°C; IR v m ai, 3340 (OH, NH, NH 2 ) , 3190 (NH, NH 2 ) , 1690 (C=O) and 1675 (C=O, C=N, C=C) cm"; UV A max [nrn (E,mM)] (pH 1) 302 (9.47),250 (8.5) , 42.51; H, 3.96; N, 22.03. Found: C, 42.20; H, 3.99; N, 21.69 . 
A mixture of 2j (0.75 g, 2.75 mmol), anhydrous CH 3CN (75 ml) and triethyl phosphite (10 ml) was stirred and heated at reflux for 6 days, while adding additional quantities of triethyl phosphite (2x5 ml) at 2 day intervals. The mixture was evaporated. The residue was triturated with Et 20 (2x50 ml) and then dissolved in MeOH (50 ml). Silica gel (25 g) was added and the mixture was evaporated. The dry powder was placed on a silica gel column (5.5x28 ern) and the column was flash-eluted with progressively increasing concentrations of MeOH in CH 2C12: 0% MeOH in 11 CH 2Cl2; 1% in 11; 2% in 11; 3% in 21; 5% in 2 1; 10% in 2 1. The eluate containing the product was evaporated and the solid residue was dried in vacuum for 16 h. The light yellow solid was stirred with 2-PrOH (20 ml) to obtain a white solid. The solid was collected and dried in vacuum at 80 DC for 16 h: 0.35 g (0.935 mmol, 34%), m.p. 186-188 DC; IR V m ax 3390, 3320 and 3210 (NH, NH 2), 1685 (C=O) and 1660 (C=O, C=N, C=C) em"; UV Am", [nm (E, mM)] (pH 1), 302 (10.0), 250 (8.92), 220 (31.2); (MeOH) 302 (9.60), 250 (8.79), 220 (29.1); (pH 11) 292 (7.94),248 (8.07),224 (9.88); IH NMR 01.23 (t, 6 H, 2 CH 3 ) , 2.84 (dd, 2 H, PCH 2 ) , 3.99 (q, 4 H, OCH 2 ) , 4.40 (br s, 2 H, NCH 2 ) , 5.55-5.63 (m,2 H, 2 CH), 6.93 (br s, 2 H, NH 2 ) and 11.14 (br s, 1 H, NH). Anal. calcd for C13HI9N40SPS (374.36): C, 41.71; H, 5.11; N, 14.97; P, 8.27 . Found: C, 41.55; H, 5.02; N, 14.64; P, 8.00.
5-Amino-3-[(E)-4-(diethoxyphosphoryl)-2-buten-1-yl]thiazolo[4,5-d]pyrimidine-2,7(3H,6H)-dione (20)
The compound was obtained, as described for the preparation of 2n, from 2k (0.75 g, 2.75 mmol) and triethyl Antiviral Chemistry & Chemotherapy 9:1 Thiazolo[4,5-djpyrimidines: anti-HCMV activity phosphite (10 plus 5 plus 5 rnl); 0.38 g (1.02 mmol, 37%), m.p.191-192 DC; IR v max 3420, 3300 and 3190 (NH, NH 2), 1690 (C=O) and 1665 broad (C=O, C=N, C=C) cm"; UV A max [nm (E, mM)] (pH 1) 302 (9.6),250 (8.71),220 (29.5); (MeOH) 302 (9.00), 250 (8.55), 220 (29.0); (pH 11) 292 (7.61),248 (7.77),224 (10.1); IH NMR 0 1.17 (t, 6 H, 2 CH 3 ) , 2.63 (dd,2 H, PCH 2 ) , 3.93 (q, 4 H, OCH 2 ) , 4.34 (br s, 2 H, NCH 2 ) , 5.43-5. 49 (m, 1 H, CH) , 5.67-5.73 (m,l H, CH), 6.95 (br s, 2 H, NH 2 ) and 11.14 (br s, 1 H, NH). Anal. calcd for C13HI9N40SPS (374.36): C, 41.71; H, 5.11; N, 14.97; P, 8.27. Found: C, 41.68; H, 4.93; N, 15.01; P, 8.11 .
Trisodium 5-Amino-3-[(Z)-4-phosphono-2buten-1-yl]thiazolo[4,5-d]pyrimidine-2, 7(3H,6H)-dione (2p) A mixture of 2n (0.45 g, 1.2 mmol), anhydrous CH 2C12 (60 ml) and bromotrimethylsilane (5 ml) was stirred at ambient temperature for 3 days. The mixture was evaporated and the residue was coevaporated with MeOH (2x20 ml), then coevaporated with CH 3CN (3x20 ml) and then stirred with CH 3CN (20 ml) to produce a solid. The solid was collected by filtration and dried in vacuum at 100 DC for 20 h; 0.38 g. The solid was dissolved in H 20 (20 ml) and the solution was applied onto a column (1.5x18 ern) of Dowex 50x8(Na+). The column was eluted with H 20 to remove UV-absorbing material. Eluate containing the product was evaporated and the residue was coevaporated with MeOH (2x50 ml). The solid was purified by reverse phase preparative HPLC using H 20 as the mobile phase. The eluate containing the homogeneous product was evaporated and the residue was coevaporated with EtOH (3x25 ml). The solid was dried in vacuum at 10QDC for 16 h; 0.18 g (0.419 mmol, 35%); UV A max [nm (E, mM)] (pH 1) 302 (8.65),250 (7.51), 222 (26.5); (pH 7.2) 302 (8.99), 250 (7.73), 222 (26.8); (pH 11) 292 (7.53),250 (7.10),224 (11.5); IH NMR 0 2.65 (dd, 2 H, PCH 2 ) , 4.39 (br s, 2 H, NCH 2 ) , 5.50-5.65 (m,2 H, 2 CH) and 7.05 (br s, 2 H, NH 2 ) . Anal. calcd for C9HgNa3N40sPS-2.5H20(429.23): C, 25.18; H, 3.05; N, 13.05; P, 7.22. Found: C, 24.75; H, 2.93; N, 12.66; P, 7.67.
Trisodium 5-amino-3-[(E)-4-phosphono-2-buten-1-yl]th iazolo [4,5-d] pyrim idi ne-2, 7(3H,6H)-d ione (2q) A mixture of2o (0.26 g, 0.695 mmol), anhydrous CH 3CN (20 ml) and bromotrimethylsilane (0.2 ml) was stirred at ambient temperature for 2 days. Additional bromotrimethylsilane (0.2 ml) was added and the mixture was heated at 80 DC for 7 h. The mixture was evaporated and the residue was suspended in H 20 (10 ml). Concentrated NH 40H (sufficient to just dissolve the solid) was added and the resulting solution was applied onto a column (1.5x19 ern) of Dowex 50x8(Na+). The column was eluted with H 20 to remove UV-absorbing material. Eluate containing the product was evaporated and the residue was purified by reverse phase preparative HPLC using H 20 as the mobile phase. The eluate containing the homogeneous product was evaporated and the residue was dried in vacuum at 100°C for 18 h; 0.12 g (0.28 mmol, 40%); UV A m ax [nm (E, mM)] (pH 1) 302 (8.08), 250 (8.03), 220 (24.0); (plI 7.2) 300 (7.58),250 (7.23),220 (24.0); (pH 11) 292 (6.71),250 (6.64),224 (9.98); IH NMR 0 2.37 (dd, 2 H, PCH 2 ) , 4.33 (br s, 2 H, NCH 2 ) , 5.50-5.65 (rn, 2 H, 2 Cll) and 6.90 (br s, 2 H, NH 2 ) . Anal. calcd for C9HsNa3N40sPSo2.5H20 (429.23): C, 25.18; H, 3.05; N, 13.05; P, 7.22. Found: C, 25.38; H, 2.63; N, 12.75; P, 5.93. 
Material and Methods: Virology
Cell lines and viruses
Human embryonic lung (HEL) fibroblasts,MRC-5 cellsand human foreskin fibroblast (HFF) cells were obtained from the ATCC. All cells were routinely propagated in MEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) and without added antibiotics.
The Towne and AD169 strains of HCMV were also obtained from the ATCC; the Davis strain was provided by S. Michelson (Institut Pasteur, Paris, France). HCMV strains D16 and C8805-37 were obtained from K. Thompson (Loyola University, Chicago, Ill., USA) and K. Biron (GlaxoWellcome, Research Triangle Park, N.C., USA), respectively. The three clinical HCMV strains (DER521, DER530 and DER648) were isolated from the urine, throat swab or blood of AIDS patients under DHPG therapy. MCMV (Smith strain) was obtained from the ATCC. HSV-1 strain 17 and HSV-2 strain HG52 were obtained from D.]. McGeoch (University of Glasgow, Glasgow, UK). HIV-1 (strain RF) was obtained from the ATCC.
The clinical HCMV isolates (DER521, DER530 and DER648) were used to infect MRC-5 cells and passaged (a mean of) eight times (range 5-11) before virus stocks were prepared. Stock preparations of HCMV (all strains), HSV-1 and HSV-2 consisted of cell-free virus obtained from the supernatant of infected cultures showing 100% cytopathic effect (CPE) that had been disrupted by freeze-thawing and clarified by low speed centrifugation. The virus stocks were stored at -80°C.
Antiviral assays
Either of two plaque reduction assayswas used as a primary screen for anti-HCMV activity. The first assay used the AD169 strain in MRC-5 cells and was conducted as described previously (Lewis et al., 1994) . The second assay used the Towne strain in MRC-5 cells and was performed as follows. Cells were seeded in 24-well plates (lOS cells/well) and the plates were incubated overnight at 37"C in a humidified 5% CO 2 atmosphere. The medium (MEM containing 10% FBS) was removed and the wells were rinsed once with fresh medium (MEM plus 2% FBS, 250 ul) before adding 40-50 p.f.u. ofHCMV (Towne strain) to each well. After 2 h of virus adsorption, the medium 58 (MEM plus 2% FBS) was removed and the cells were rinsed once with fresh medium (MEM plus 2% FBS, 250 ul). Varying concentrations of the test compound or control drug in culture medium (1 rnl) were added to appropriate wells and the plates were incubated for 6 days at 37°C in a humidified 5% CO 2 atmosphere. Each concentration of drug was tested in duplicate wells. The . medium was removed and 0.1% crystal violet in 20% MeOH (200 ul) was added to each well. After 10 min, the staining solution was removed, cells were rinsed in tap water and the plates were dried at ambient temperature. Plaques were counted using a Nikon inverted microscope.
The anti-HCMV activity of compound 21 was confirmed by two additional plaque reduction assays which used the Towne strain in HFF cells and the Davis strain in HEL cells. These assays were conducted as previously reported (Lewis etal., 1994; Neyts etal., 1994) .
The ability of 21 to inhibit the DHPG-resistant strains D16 and C8805-37 was determined in identical plaque reduction assays as used for the AD169 strain in MRC-5 cells. Inhibition of the HCMV isolates DER521, DER530 and D ER648 in HEL cells was assayed in the manner used for the Davis strain of HCMV and inhibition of MCMV was assayed as described by Neyts et al. (1994) .
Studies with HSV-1 and HSV-2 used a CPE assay as described in a previous publication (Lewis et al., 1994) . The HIV-1 CPE assay was performed as previously described .
Antiviral activity is expressed as IC so, which represent the compound concentration required to reduce virus plaque formation by 50%. All HCMV assays used DHPG as a positive control. HPMPC was used as the positive control in the MCMV experiments, whereas ACV served as the control in the HSV experiments and ddC was the reference compound used in the HIV assay.
Cytotoxicity assays
The toxicity of the test compounds to stationary cells was assayed by either of two methods. In the first assay, cytotoxicity was scored visually as described in a previous publication (Lewis et al., 1994) . The alternate assay was conducted as follows. Uninfected, stationary MRC-5 or Vero cells were resuspended in MEM supplemented with 10% FBS. The viable cells (determined by trypan blue staining) were dispensed into 96-well (lx10 4 cells/well) microtitre plates. Varying concentrations of test compound or control compound (in medium, 20~ll) were added to the appropriate wells and the plates were incubated at 37"C in a humidified 5% CO 2 atmosphere for 6 days. Each concentration of the test compound was assayedin quadruplicate. The toxic effect for each concentration of drug was determined by using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation (MTS) Assay (Promega) as directed by the manufacturer's instructions. The average absorbance for each concentration of test compound was graphed and the data obtained was used to calculate a TC so (concentration 
Other assays
The effects of variation in virus m.o.i. and time of drug addition on the ability of the compounds to inhibit virus replication were assayed by methods described previously (Lewis etal., 1994) . 
Results
-CH 2CH=CHCH2CI (E) -CH 2CH=CHCH20H (Z) -CH 2CH=CHCH20H (E) -CH 2CH=CHCH2P(O)(OEt), (Z) -CH 2CH=CHCH2P(O)(OEt), (E) -CH 2CH=CHCH2P03H2 (Z) -CH 2CH=CHCH2P03H2 (E)
Chemistry
Compounds 2b, d, f, h,j and k (Fig. 1) were obtained from the direct alkylation of the sodium salt of 1 (Baker & Chatfield, 1970) . The synthesis of 2d and 2f required the prior preparation of (2-acetoxyethoxy)methyl bromide (Robins & Hatfield, 1982) and 2-(bromomethoxy)-1,3propanediyl dibenzoate (Beauchamp et aI., 1988) , respectively, whereas 2b, h, j and k were prepared from commercially available alkyl halides. The temperature and duration of reaction were varied to accommodate a difference in the reactivity of the respective alkyl halide but specific reaction conditions and isolation methodology were not optimized. With respect to the reaction of the anion of 1 with the dichlorobutenes, no attempt was made to isolate or identify the potential products resulting from displacement of both halogens. The site of alkylation was assigned in each case by comparisons of the UV spectra for the compounds of structure 2 with the spectra of the established 3-[(Z)-2-penten-l-yl]-derivative 2a (Lewis et al., 1995) , The geometry about the olefinic bond for compounds 2j and 2kwas confirmed by IH NMR coupling constants. Only traces of the opposite isomer was detected in each case. Treatment of2b and 2d with NH 3 produced the HBG analogue 2c and the ACV analogue 2e, respectively. Treatment of 2f with methoxide yielded the gancic10vir analogue 2g, whereas the diol 2i was obtained from the acidic hydrolysis of 2h. The treatment of 2j or 2k with hot, dilute HCl produced 21 or 2m. The phosphonate diester 2n or 20 was readily obtained from the treatment of the appropriate chlorobutene, 2j or 2k, with triethyl phosphite. Basic hydrolysis of the phosphonate diesters resulted in a ring opening in the aglycon; however, 2p and 2q were obtained from the treatment of the respective diester with bromotrimethylsilane and were isolated and characterized in the form of their trisodium salts. The sensitivity of the thiazole ring in 3-substituted thiazolo]4,5-d]pyrimidines to nuc1eophiles has been noted previously (Nagahara et al., 1990) .
resulting in 50% cell death) for each test compound.
Analysis of toxicity of 21 to growing cells was performed as previously described (Lewis et aI., 1994) . Compound 21 was also tested for its toxic effect on human bone marrow cells as previously described by Sommadossi et al. (1992) . DHPG was used as a toxicity control in all cytotoxicity assays.
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Biological studies Compounds 2c, e, g, i-m, p and q were evaluated for their anti-HCMV activity by plaque reduction assays using either the AD169 or the Towne strain of HCMV in MRC-5 cells and for visual cytotoxic effect by methods previously described (Lewis et aI., 1994) . Only 2g (IC so 56 LM; AD169 strain) and 21 nc, 1.1~LM; AD169 strain) exhibited anti-HCMV activity, but only for 21 was this (Tatarowicz et al., 1992) ' and the C8805-37 strain is reportedly (Biron, 1991; Stanat et al., 1991) mutated in the UL97 phosphotransferase gene, which encodes the protein kinase used for the phosphorylation ofDHPG. The C8805-37 strain was resistant to 21, which suggests that phosphorylation is essential to its activity; in contrast, the polymerase mutant (D16) did not show resistance to 21. Additionally, the isolates (DER521, DER530 and DER648), which were resistant to DHPG, were not cross-resistant to 21.
The effect of 21 against other herpesviruses was also determined using methodologies previously reported (Bhattacharya et al., 1995; Neyts et al., 1994) . In contrast to its potent HCMV activity, 21 was ineffective in the in vitro inhibition of murine cytomegalovirus (MCMV). Additionally, 21 failed to inhibit HSV-1 or HSV-2. Also as shown in Table 1 ,21 did not inhibit HIV-l.
The toxic effect of 21 to cultured cells was monitored with static Vero, HFF and MRC-5 cells and growing Vero, MRC-5, KB and THP-1 cells, as well as human bone marrow progenitor cells. In Vero, MRC-5, KB and THP-1 cells the observed median toxic concentrations (TC so ) ranged from 100 to >1000 f!M ( Table 2) . The observed toxic effect of this compound on bone marrow progenitor cells was about the same as that observed for DHPG ( Table 2) .
To assess the effect of viral input on the activity of 21, it was added to MRC-5 cells after infection with HCMV (Towne strain) at various m.o.i, Six days post-infection, the ©1998 International Medical Press Thiazolo[4, 
Discussion
round of virus replication would be observed as a decrease in overall virus titre obtained during a subsequent round of infection. The level of virus expression was monitored at day 7 post-initial infection as previously described (Lewis et a!., 1994) . The results of this experiment showed that 21 (similar to 2a; Lewis et al., 1994) maintained its full antiviral activity when added up to 36 h post-infection, while DHPG maintained most of its activity when added up to 48 h post-infection ( Fig. 3 ).
Ten~lg of 21 (0) or DHPG (0) was added at various times post-infection to MRC-5 cells infected with HCMV (Towne strain) at an m.o.i. of 0.02. At 7 days post-infection, the cells were lysed by freeze-thawing and the titre of the virus in the cell lysate was determined. Each data point is an average of three or more separate experiments performed in duplicate.
In direct comparisons to DHPG, compound 21 showed equal or better activity as an anti-HCMV agent against low viral loads and comparable toxicities to uninfected cells. Although 21 was perhaps less potent than 2a (IC so 0.2-0.4~lM), it was significantly less toxic in most of the cell cultures tested (Lewis et al., 1994) . However, like 2a, compound 21 is sensitive to m.o.i. and, as the time of drug addition experiment demonstrated, must be added to cells during the early stages of virus infection.
A comparison of the anti-HCMV activity of 21 (IC so 1-4 u.M) with 2m (IC so >196~lM) suggests a parallel with the anti-HSV-1 activity (see above) of the E and Z isomers of 9-(4-hydroxy-2-butenyl)guanine (Larsson et al., 1983; Hua eta!., 1987) ; however, with guanine as the aglycon, the saturated analogue (HBG) was found equally inhibitory to HSV-1, whereas 2c (IC so >390 u.M) showed no activity in our HCMV assay. This dissimilarity may be attributable to 1000 o.aa1-r"'"T""'l'TTTmr-r-r""""mr-"'T""T"T'TTI.... culture plates were subjected to one round of freezing and thawing and the virus titre was then determined as described in a previous publication (Lewis et al., 1994) .
The results of this experiment showed that the antiviral activity of 21 decreased with an increase in m.o.i, (Fig. 2a ) with IC so values ranging from 0.24~lM (m.o.i. 0.004) to -200~lM (m.o.i. 4) . In contrast, the antiviral activity of DHPG was much less dependent on the m.o.i. variations tested (Fig. 2b) .
To define the point of drug intervention during the virus life cycle, a timing experiment was performed in which a low m.o.i. was used and the virus titre was monitored after at least two rounds of virus replication. In this assay, the effect of timing of drug addition during the first (b) 1000 0.1 1 10 100
Concentration of DHPG (11M) Selected m.o.i. of HCMV (0.004,0; 0.04,0; 0.4, 0; 4.0, L1) were used to infect MRC-5 cells which were then treated in a dose-response fashion with either 21 (a) or DHPG (b). At 6 days post-infection the cells were lysed by freezethawing and the titre of the virus present in the cell Iysates was determined. differences in the two heterocycles or may be a further illustration of the differences between the two viruses. The finding of anti-HSV-1 activity for 2a (Lewis et al., 1994) but no similar activity for 21 supports the latter alternative.
In conclusion, we have found that 21 has potent anti-HCMV activity, which is unique in that it is the only hydroxylated derivative (including the riboside; Lewis et al., 1995; Nagahara et al., 1990 ) of 1 to exhibit significant in vitro activity. Although the resistance of the kinase mutant (C8805-37) suggests that phosphorylation is needed for 21 to exert its antiviral effect, the monophosphate mimic of 21, 2p, was found to be inactive. The reason for the high structural specificity with regard to anti-HCMV activity for structure 21 is at this point unclear.
